David G. Lester
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David G. Lester has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Guy Thompson
Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
4 shared publications - Martin R. Turner
Nuffield Department of Clinical Neurosciences, Oxford University , Oxford OX3 9DU
3 shared publications - Eran Hornstein
Department of Molecular Genetics, Weizmann Institute of Science
2 shared publications Hadar Klimovski
Department of Molecular Genetics
2 shared publications- Johnathan Cooper-Knock
University of Sheffield
2 shared publications Kevin Talbot
Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford
2 shared publications
Latest Publications
- Open Access
Circulating protein profiling identifies prognostic biomarkers in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive motor neuron loss and significant clinical variability. Blood-based biomarkers offer a scalable approach to stratify patients and support therapeutic development. In a large-scale serum proteomic survival study of ALS, we analyzed 741 patients from independent cohorts in Israel and the UK to identify blood proteins linked to ALS survival. The cohorts were profiled using complementary proteomics technologies, mass spectrometry and the Olink proximity extension assay (PEA), enabling cross-cohort and cross-platform evaluation of concordant protein effects. We identified 19 serum proteins associated with ALS survival across two independent cohorts profiled using orthogonal proteomic platforms. Among these, GSN and IGFBP2 improved survival prediction and patient stratification compared to established clinical covariates and provided additional prognostic information compared to serum neurofilament light chain (NfL). These novel circulating protein biomarker candidates may improve prognostic assessment and support future precision-medicine approaches in ALS.
Open AccessCirculating protein profiling identifies prognostic biomarkers in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive motor neuron loss and significant clinical variability. Blood-based biomarkers offer a scalable approach to stratify patients and support therapeutic development. In a large-scale serum proteomic survival study of ALS, we analyzed 741 patients from independent cohorts in Israel and the UK to identify blood proteins linked to ALS survival. The cohorts were profiled using complementary proteomics technologies, mass spectrometry and the Olink proximity extension assay (PEA), enabling cross-cohort and cross-platform evaluation of concordant protein effects. We identified 19 serum proteins associated with ALS survival across two independent cohorts profiled using orthogonal proteomic platforms. Among these, GSN and IGFBP2 improved survival prediction and patient stratification compared to established clinical covariates and provided additional prognostic information compared to serum neurofilament light chain (NfL). These novel circulating protein biomarker candidates may improve prognostic assessment and support future precision-medicine approaches in ALS.
- Open Access
A proteomic signature for prognostic stratification in amyotrophic lateral sclerosis
In the pathologically and clinically heterogeneous neurodegenerative disorder amyotrophic lateral sclerosis (ALS), objective biochemical predictors of survival are essential to handle complexity in clinical trials, enrich clinical decision-making and interrogate the biology of disease progression. In this longitudinal study, we performed high-depth proximity extension assay proteomics using 1,095 samples of serum ( N =851) and CSF ( N =244) from 426 people with ALS, with orthogonal replication in an external cohort of 349 people with ALS. Age- and sex-adjusted Cox analysis identified 57 proteins in serum, including neurofilament light chain (NEFL) and peripherin, as well as five proteins in CSF, including tropomyosin 3 (TPM3) that were associated with survival (FDR-adjusted p<0.05). Penalised Cox regression identified a panel of 9 serum proteins – including NEFL, peripherin, TNF receptor superfamily member 27 (EDA2R) and calcitonin – that reflect the extent of disease as well as the progression rate, improving survival prediction compared with models using clinical parameters and NEFL. Joint modelling identified associations between the longitudinal trajectories of serum EDA2R and calcitonin with survival, highlighting their potential role in measuring disease progression. This work indicates the utility of multiple proteins reflecting diverse biological pathways in refining survival stratification and highlights systemic factors in ALS progression.
Open AccessA proteomic signature for prognostic stratification in amyotrophic lateral sclerosis
In the pathologically and clinically heterogeneous neurodegenerative disorder amyotrophic lateral sclerosis (ALS), objective biochemical predictors of survival are essential to handle complexity in clinical trials, enrich clinical decision-making and interrogate the biology of disease progression. In this longitudinal study, we performed high-depth proximity extension assay proteomics using 1,095 samples of serum ( N =851) and CSF ( N =244) from 426 people with ALS, with orthogonal replication in an external cohort of 349 people with ALS. Age- and sex-adjusted Cox analysis identified 57 proteins in serum, including neurofilament light chain (NEFL) and peripherin, as well as five proteins in CSF, including tropomyosin 3 (TPM3) that were associated with survival (FDR-adjusted p<0.05). Penalised Cox regression identified a panel of 9 serum proteins – including NEFL, peripherin, TNF receptor superfamily member 27 (EDA2R) and calcitonin – that reflect the extent of disease as well as the progression rate, improving survival prediction compared with models using clinical parameters and NEFL. Joint modelling identified associations between the longitudinal trajectories of serum EDA2R and calcitonin with survival, highlighting their potential role in measuring disease progression. This work indicates the utility of multiple proteins reflecting diverse biological pathways in refining survival stratification and highlights systemic factors in ALS progression.
- Open Access
- 8 July 2025
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (9) , 1907-1912
A Validated Model to Predict Severe Weight Loss in Amyotrophic Lateral Sclerosis
Severe weight loss in amyotrophic lateral sclerosis (ALS) is common, multifactorial, and associated with shortened survival. Using longitudinal weight data from over 6000 patients with ALS across three cohorts, we built an accelerated failure time model to predict the risk of future severe (≥ 10%) weight loss using five single‐timepoint clinical predictors: symptom duration, revised ALS Functional Rating Scale, site of onset, forced vital capacity, and age. Model performance and generalisability were evaluated using internal–external cross‐validation and random‐effects meta‐analysis. The overall concordance statistic was 0.71 (95% CI 0.63–0.79), and the calibration slope and intercept were 0.91 (0.69–1.13) and 0.05 (−0.11–0.21). This study highlights clinical factors most associated with severe weight loss in ALS and provides the basis for a stratification tool.
- 8 July 2025
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (9) , 1907-1912
Open AccessA Validated Model to Predict Severe Weight Loss in Amyotrophic Lateral Sclerosis
Severe weight loss in amyotrophic lateral sclerosis (ALS) is common, multifactorial, and associated with shortened survival. Using longitudinal weight data from over 6000 patients with ALS across three cohorts, we built an accelerated failure time model to predict the risk of future severe (≥ 10%) weight loss using five single‐timepoint clinical predictors: symptom duration, revised ALS Functional Rating Scale, site of onset, forced vital capacity, and age. Model performance and generalisability were evaluated using internal–external cross‐validation and random‐effects meta‐analysis. The overall concordance statistic was 0.71 (95% CI 0.63–0.79), and the calibration slope and intercept were 0.91 (0.69–1.13) and 0.05 (−0.11–0.21). This study highlights clinical factors most associated with severe weight loss in ALS and provides the basis for a stratification tool.
- Open Access
- 16 May 2025
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 96 (10) , 1008-1011
Progression and life expectancy in primary lateral sclerosis
Objectives To characterise the clinical characteristics and longitudinal outcomes in primary lateral sclerosis (PLS), including median survival from symptom onset and age at death. Methods The authors retrospectively reviewed electronic health records of patients diagnosed with PLS referred to a specialised motor neuron disorders clinic from 2002 to 2024, analysed longitudinal Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) assessments using joint models and used Kaplan-Meier methods and life tables to calculate median survival and age at death compared with population-based values. Results Of 52 patients, 34 (65%) were male, 41 (79%) first noted symptoms in the lower limbs and 10 (19%) in corticobulbar function. Median age of symptom onset was 53 years. The mean annual rate of functional decline was −1.92 ALSFRS-R points (95% CI −3.03 to −0.78), with equal highest rates of decline in fine and gross motor subscores. Five patients (10%) received gastrostomy and three (6%) non-invasive ventilation. Median survival from symptom onset was 23.1 years (22.7 to not reached), and median age at death was 79.5 years (77.8 to not reached) compared with a population-based reference mean of 81.9 years (81.1 to 82.8). Discussion PLS may be commensurate with near-normal life expectancy. Significant disability arises from limb motor dysfunction, with a minority of patients requiring nutritional or respiratory support. This has important implications for counselling and trial design.
- 16 May 2025
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 96 (10) , 1008-1011
Open AccessProgression and life expectancy in primary lateral sclerosis
Objectives To characterise the clinical characteristics and longitudinal outcomes in primary lateral sclerosis (PLS), including median survival from symptom onset and age at death. Methods The authors retrospectively reviewed electronic health records of patients diagnosed with PLS referred to a specialised motor neuron disorders clinic from 2002 to 2024, analysed longitudinal Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) assessments using joint models and used Kaplan-Meier methods and life tables to calculate median survival and age at death compared with population-based values. Results Of 52 patients, 34 (65%) were male, 41 (79%) first noted symptoms in the lower limbs and 10 (19%) in corticobulbar function. Median age of symptom onset was 53 years. The mean annual rate of functional decline was −1.92 ALSFRS-R points (95% CI −3.03 to −0.78), with equal highest rates of decline in fine and gross motor subscores. Five patients (10%) received gastrostomy and three (6%) non-invasive ventilation. Median survival from symptom onset was 23.1 years (22.7 to not reached), and median age at death was 79.5 years (77.8 to not reached) compared with a population-based reference mean of 81.9 years (81.1 to 82.8). Discussion PLS may be commensurate with near-normal life expectancy. Significant disability arises from limb motor dysfunction, with a minority of patients requiring nutritional or respiratory support. This has important implications for counselling and trial design.
- 1 January 2005
- Published by Springer Nature
- Vol. 62, 357-384
Clinical drug evaluation using imaging readouts: regulatory perspectives
- 1 January 2005
- Published by Springer Nature
- Vol. 62, 357-384
Clinical drug evaluation using imaging readouts: regulatory perspectives